Kefrenex

Quetiapine, the active ingredient in Kefrenex, is an atypical antipsychotic presented as an oral tablet for oral use. It is prescribed to manage symptoms of schizophrenia, bipolar disorder, and as an adjunctive treatment for major depressive disorder in adult patients.

GNH USA supplies Kefrenex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards, provides regulatory documentation, and offers reliable logistics for global distribution. Clients benefit from competitive pricing and dedicated technical support throughout the procurement process.

Quetiapine is used in the management of several psychiatric disorders by modulating neurotransmitter activity.

- Schizophrenia: reduces psychotic symptoms such as hallucinations and delusions. - Bipolar disorder: stabilizes mood and decreases manic or depressive episodes. - Major depressive disorder (adjunctive therapy): enhances antidepressant response when added to standard treatment.

Quetiapine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness or sedation - Dry mouth - Constipation - Weight gain - Dizziness or light‑headedness

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe hypotension - Agranulocytosis (rare)

When prescribing quetiapine, clinicians should observe several safety considerations.

- Dose titration: start low and increase gradually to minimize sedation and orthostatic effects. - Cardiovascular monitoring: assess blood pressure and heart rate, especially in patients with pre‑existing hypertension. - Metabolic screening: monitor weight, glucose and lipid levels periodically due to risk of metabolic changes. - CNS effects: advise patients not to operate machinery or drive until they know how the drug affects them. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Quetiapine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase quetiapine plasma concentrations, raising risk of toxicity. - CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce quetiapine levels, diminishing therapeutic effect. - Antihypertensive agents: enhanced hypotensive response due to additive blood pressure lowering.